BNTX - BioNTech SE
NYSE * Healthcare * Biotechnology
$107.19
+$5.01 (+4.90%)
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
BNTX Key Statistics
Market Cap
$25.64B
P/B Ratio
1.19
EPS
$-2.78
Revenue Growth
+0.2%
Profit Margin
-0.2%
Employees
6,772
How BNTX Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
#6
of 6
Growth Rank
#1
of 6
Size Rank
#6
of 6
| Company | Market Cap | P/E | Rev Growth | Margin | Compare |
|---|---|---|---|---|---|
| BNTX(This stock) | $25.64B | N/A | 0.2% | -0.2% | - |
| AMGNAmgen Inc | $175.30B | 25.2 | 0.1% | 0.2% | vs AMGN |
| GILDGilead Sciences | $152.12B | 19.0 | 0.0% | 0.3% | vs GILD |
| VRTXVertex Pharmaceuticals | $118.09B | 32.4 | 0.1% | 0.3% | vs VRTX |
| REGNRegeneron Pharmaceuticals | $81.40B | 18.4 | 0.0% | 0.3% | vs REGN |
| BIIBBiogen Inc | $27.23B | 16.9 | 0.0% | 0.2% | vs BIIB |
BioNTech SE Company Information
- Headquarters
- An der Goldgrube 12, Mainz, Germany, 55131, undefined
- Website
- www.biontech.de
- Sector
- Healthcare
- Industry
- Biotechnology